Status:
COMPLETED
Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Atrophic Vaginitis
Atrophy
Eligibility:
FEMALE
45-80 years
Phase:
PHASE3
Brief Summary
This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.
Eligibility Criteria
Inclusion
- Generally healthy postmenopausal women with symptoms of atrophic vaginitis including vaginal dryness, vaginal itching, vaginal burning, and/or painful intercourse.
- The subject must have a clinical diagnosis of atrophic vaginitis and an intact uterus.
Exclusion
- Women who do not have a clinical diagnosis of atrophic vaginitis.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2007
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT00137371
Start Date
August 1 2005
End Date
September 1 2007
Last Update
December 10 2007
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Tucson, Arizona, United States, 85715
2
Encinitas, California, United States, 92024
3
San Diego, California, United States, 92108
4
Torrance, California, United States, 90502